Domestic Ban on Sale of Celebrex Suggested by Pharmacist Group

In an official statement released on December 21st, the Korean Pharmacists for Democratic Society (KPDS) strongly suggested that Pfizer should withdraw Celebrex, a Cox-2 inhibitor for treatment of pain and inflammation, from the domestic market.

The statement is reflective of the recent announcement by the U.S. Food and Drug Administration (FDA) that it has great concerns for serious safety ...